Bristol-Myers Squibb Co (XSWX:BMY) Growth Rank: 4 (As of Jul. 28, 2026) — 50% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BMY Bristol-Myers Squibb Co XSWX:BMY
75 GF Score
Price CHF51.44
GF Value CHF45.29
! 7 Warning Signs
View Full Analysis

What is Bristol-Myers Squibb Co Growth Rank?

Bristol-Myers Squibb Co XSWX:BMY +1.56% 75 Growth Rank is 4 as of Jul. 28, 2026, which is 50% below its 10-year median of 8.00. GuruFocus rates XSWX:BMY with a GF Score™ of 75/100 and a GF Value™ of CHF45.29. The stock has 7 warning signs investors should review.

Bristol-Myers Squibb Co has the Growth Rank of 4.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Bristol-Myers Squibb Co Growth Rank Related Terms

XSWX:BMY vs PFE, GILD, AMGN: Growth Rank Comparison

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bristol-Myers Squibb Co Growth Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Growth Rank distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's Growth Rank falls into.


XSWX:BMY
75GF Score
Bristol-Myers Squibb Co XSWX:BMY
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 4 mean?
Bristol-Myers Squibb Co (XSWX:BMY) has a Growth Rank of 4 as of Jul. 28, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Bristol-Myers Squibb Co and its competitors. This is 50% below median its historical median of 8.00. Over the past decade, Bristol-Myers Squibb Co's Growth Rank has ranged from 4.00 to 10.00.
Is Bristol-Myers Squibb Co's Growth Rank too high?
Bristol-Myers Squibb Co's current Growth Rank of 4 is 50% below median its 10-year median of 8.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 10.00. Overall, Bristol-Myers Squibb Co has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Growth Rank compare to PFE and GILD?
Bristol-Myers Squibb Co's Growth Rank of 4 can be compared against companies in the Drug Manufacturers industry. Historically, Bristol-Myers Squibb Co's own Growth Rank has ranged from 4.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Drug Manufacturers company?
A good Growth Rank depends on the Drug Manufacturers industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Bristol-Myers Squibb Co and its competitors. Bristol-Myers Squibb Co's current Growth Rank is 4, which is 50% below median its own 10-year median of 8.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Bristol-Myers Squibb Co (XSWX:BMY) has a current Growth Rank of 4. The stock's GF Value™ is CHF45.29, compared to a current price of CHF51.44 — trading 13.6% above its estimated fair value. The current Growth Rank is 4, which is 50% below median its 10-year median of 8.00. Bristol-Myers Squibb Co's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Bristol-Myers Squibb Co (XSWX:BMY), the current Growth Rank is 4 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bristol-Myers Squibb Co (XSWX:BMY) Overvalued in 2026?

Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued. The current stock price of CHF51.44 is trading 13.6% above its estimated GF Value™ of CHF45.29.

Key valuation signals for XSWX:BMY:

  • Growth Rank: 4 (50% below median its 10-year median of 8.00)
  • GF Value™: CHF45.29 vs. price of CHF51.44 (13.6% above fair value)
  • GF Score™: 75/100 with 7 warning signs

No single metric tells the full story. See the XSWX:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bristol-Myers Squibb Co Business Description

Address Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
75GF Score

Get the complete analysis for XSWX:BMY

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF51.44
Price
CHF45.29
GF Value